These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn's disease. Hartman C; Berkowitz D; Weiss B; Shaoul R; Levine A; Adiv OE; Shapira R; Fradkin A; Wilschanski M; Tamir A; Shamir R Isr Med Assoc J; 2008 Jul; 10(7):503-7. PubMed ID: 18751627 [TBL] [Abstract][Full Text] [Related]
3. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease. Tanaka T; Takahama K; Kimura T; Mizuno T; Nagasaka M; Iwata K; Nakano H; Muramatsu M; Takazoe M J Gastroenterol Hepatol; 2006 Jul; 21(7):1143-9. PubMed ID: 16824066 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of nutritional therapy for perforating and non-perforating Crohn's disease. Ikeuchi H; Yamamura T; Nakano H; Kosaka T; Shimoyama T; Fukuda Y Hepatogastroenterology; 2004; 51(58):1050-2. PubMed ID: 15239244 [TBL] [Abstract][Full Text] [Related]
5. Usefulness of an elemental diet in Crohn's disease. Takahashi H; Ando T; Watanabe O; Maeda O; Ishiguro K; Ohmiya N; Niwa Y; Goto H Inflammopharmacology; 2007 Feb; 15(1):15-7. PubMed ID: 17323189 [TBL] [Abstract][Full Text] [Related]
6. Factors affecting recurrence in patients with Crohn's disease under nutritional therapy. Esaki M; Matsumoto T; Nakamura S; Yada S; Fujisawa K; Jo Y; Iida M Dis Colon Rectum; 2006 Oct; 49(10 Suppl):S68-74. PubMed ID: 17106818 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial. Takagi S; Utsunomiya K; Kuriyama S; Yokoyama H; Takahashi S; Iwabuchi M; Takahashi H; Takahashi S; Kinouchi Y; Hiwatashi N; Funayama Y; Sasaki I; Tsuji I; Shimosegawa T Aliment Pharmacol Ther; 2006 Nov; 24(9):1333-40. PubMed ID: 17059514 [TBL] [Abstract][Full Text] [Related]
8. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Verma S; Brown S; Kirkwood B; Giaffer MH Am J Gastroenterol; 2000 Mar; 95(3):735-9. PubMed ID: 10710067 [TBL] [Abstract][Full Text] [Related]
9. Medical therapy for refractory pediatric Crohn's disease. Faubion WA; Bousvaros A Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1199-213. PubMed ID: 16872913 [TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of antimycobacterial therapy for Crohn's disease. Borgaonkar MR; MacIntosh DG; Fardy JM Am J Gastroenterol; 2000 Mar; 95(3):725-9. PubMed ID: 10710065 [TBL] [Abstract][Full Text] [Related]
11. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Egan LJ; Sandborn WJ; Tremaine WJ Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654 [TBL] [Abstract][Full Text] [Related]
12. Relationship between nutritional therapy and surgery in Crohn's disease. Takahashi H; Ando T; Watanabe O; Maeda O; Ishiguro K; Ishikawa D; Hasegawa M; Minami M; Goto Y; Kusugami K; Ina K; Ohmiya N; Niwa Y; Goto H Hepatogastroenterology; 2009; 56(93):1044-8. PubMed ID: 19760938 [TBL] [Abstract][Full Text] [Related]
13. Medical treatment of Crohn's disease of the colon. Jones FA Bibl Gastroenterol; 1970; (9):143-4. PubMed ID: 5538376 [No Abstract] [Full Text] [Related]
14. Enteral nutrition improves health-related quality of life in Crohn's disease patients with long disease duration. Kuriyama M; Kato J; Morimoto N; Fujimoto T; Kono H; Okano N; Miyaike J; Morita T; Okada H; Suzuki S; Yoshioka T; Shiode J; Shiratori Y; Kazuhide Y; Hepatogastroenterology; 2009; 56(90):321-7. PubMed ID: 19579591 [TBL] [Abstract][Full Text] [Related]
15. Dietary treatment of active Crohn's disease. Diet is the best treatment. King TS; Woolner JT; Hunter JO BMJ; 1997 Jun; 314(7097):1827-8. PubMed ID: 9224093 [No Abstract] [Full Text] [Related]
16. [Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients]. de Ridder L; Escher JC; Taminiau JA Ned Tijdschr Geneeskd; 2002 Oct; 146(40):1879-83. PubMed ID: 12395595 [TBL] [Abstract][Full Text] [Related]
17. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340 [TBL] [Abstract][Full Text] [Related]
18. The frequency of sister chromatid exchanges in patients with Crohn's disease and the effect of therapy with "anti-tumor necrosis factor" on this frequency. Danalioglu A Hepatogastroenterology; 2009; 56(91-92):729-33. PubMed ID: 19621692 [TBL] [Abstract][Full Text] [Related]
19. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Korzenik JR; Dieckgraefe BK Aliment Pharmacol Ther; 2005 Feb; 21(4):391-400. PubMed ID: 15709989 [TBL] [Abstract][Full Text] [Related]
20. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties. Tromm A; Griga T; May B Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]